Skip to main content
Egetis Therapeutics logo

Egetis Therapeutics — Investor Relations & Filings

Ticker · EGTX ISIN · SE0003815604 LEI · 549300RZCKGWRUBPMY22 ST Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2023-04-27 AGM Information
Country SE Sweden
Listing ST EGTX

About Egetis Therapeutics

https://www.egetis.com/

Egetis Therapeutics is an innovative and integrated pharmaceutical company focused on developing and commercializing treatments for serious and rare diseases with significant unmet medical needs. The company's strategy centers on advancing drug candidates through late-stage clinical development to market approval. Its primary asset, Emcitate (tiratricol), is a first-in-class drug candidate in late-stage development for the treatment of Monocarboxylate Transporter 8 (MCT8) deficiency, a rare congenital disorder of thyroid hormone transport.

Recent filings

Filing Released Lang Actions
Bulletin from Egetis Therapeutics’ Annual General Meeting 2023
AGM Information Classification · 98% confidence The document is explicitly titled 'Bulletin from Egetis Therapeutics' Annual General Meeting 2023' and details the resolutions passed during the AGM held on April 27, 2023, including board elections, remuneration approvals, and authorization for share issuance. This content directly corresponds to the definition of AGM Information. Although it mentions that the complete minutes will be made available later, the document itself is a summary bulletin of the meeting's outcomes, making AGM-R the most appropriate classification over RPA or RNS.
2023-04-27 English
Kommuniké från Egetis Therapeutics årsstämma 2023
AGM Information Classification · 99% confidence The document is explicitly titled 'Kommuniké från Egetis Therapeutics årsstämma 2023' (Communiqué from Egetis Therapeutics Annual General Meeting 2023). It details decisions made during the meeting, such as the approval of financial statements, election of board members, determination of director fees, appointment of auditors, and approval of incentive programs. These contents are characteristic of materials presented or summarized following an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R.
2023-04-27 Swedish
Earnings Release 2023
Earnings Release Classification · 99% confidence The document contains a detailed 'Finansiell översikt' (Financial overview) with comparative figures for Q1 2023, Q1 2022, and FY 2022, including revenue, net result, cash flow, and EPS. It also includes a 'VD har ordet' (CEO's word) section discussing financing activities (a directed new share issue) and extensive updates on clinical trial progress (Emcitate and Aladote) with specific regulatory milestones (EMA MAA submission planned for Q2 2023, US NDA submission planned for Q4 2023). The structure, content (financial tables, management commentary, pipeline updates), and reporting period focus strongly indicate this is a comprehensive report covering a period shorter than a full year, specifically the first quarter. This aligns perfectly with the definition of an Interim/Quarterly Report (IR). It is not a brief announcement (RPA/ER) because it contains detailed financial tables and extensive narrative analysis. Q2 2023
2023-04-26 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for Egetis Therapeutics covering the period of January-March 2023. It includes detailed financial tables (Net revenues, Result after tax, Cash flow, etc.), management commentary from the CEO, project updates, and operational highlights. Since it covers a period shorter than a full fiscal year and contains substantive financial data and analysis, it is classified as an Interim/Quarterly Report. Q2 2023
2023-04-26 English
Egetis comments on market rumors
Legal Proceedings Report Classification · 99% confidence The document is a short press release dated March 30, 2023, addressing market rumors regarding a potential acquisition of Egetis Therapeutics. It explicitly states that discussions are ongoing regarding a potential takeover offer. This type of announcement, concerning M&A activity or takeover bids, directly aligns with the definition of 'M&A Activity (Code: TAR)'. Although it is a brief statement, its core subject matter is the takeover rumor, not just announcing the publication of a separate report (which would suggest RPA or RNS). The content is a direct communication about a takeover proposal/rumor.
2023-03-30 English
Egetis kommenterar förekommande rykten på marknaden
M&A Activity Classification · 95% confidence The document is a short press release from Egetis Therapeutics AB dated March 30, 2023. The primary content addresses market rumors regarding a potential takeover bid ('potentiellt bud på bolaget'). It explicitly states that discussions are ongoing but there is no guarantee of an offer. The text concludes with boilerplate company information and a link to the actual document/announcement. Crucially, the document states: 'Denna information är sådan information som Egetis Therapeutics är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning.' This indicates a mandatory regulatory disclosure concerning potential M&A activity. Since the document is short and serves as an official announcement regarding a market event (potential takeover/bid), it fits best under the M&A Activity category (TAR). It is not a full report (10-K, IR) nor a general regulatory filing (RNS), but a specific announcement about a takeover proposal.
2023-03-30 Swedish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.